Difference between revisions of "Pracinostat (SB-939)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
HDAC inhibitor | HDAC inhibitor | ||
| − | =History of changes in FDA indication= | + | ==History of changes in FDA indication== |
*2/27/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leulemia]]. | *2/27/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leulemia]]. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' SB939 | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
Revision as of 23:28, 23 February 2021
Mechanism of action
HDAC inhibitor
History of changes in FDA indication
- 2/27/2014: Granted FDA orphan drug status for treatment of acute myeloid leulemia.
Also known as
- Code name: SB939